OTSKF News and Press, Otsuka Holdings Co. Ltd.

2024-06-18 07:05:27 ET More on AstraZeneca AstraZeneca: The Price Upside Is Exhausted For Now (Rating Downgrade) AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZen...

2024-05-22 12:29:46 ET More on Otsuka Historical earnings data for Otsuka Holdings Co., Ltd. Dividend scorecard for Otsuka Holdings Co., Ltd. Financial information for Otsuka Holdings Co., Ltd. Seeking Alpha’s Quant Rating on Otsuka Holdings Co., Ltd. ...

2024-04-30 09:30:31 ET More on Otsuka Holdings Co., Ltd. Seeking Alpha’s Quant Rating on Otsuka Holdings Co., Ltd. Historical earnings data for Otsuka Holdings Co., Ltd. Read the full article on Seeking Alpha For further details see: Otsuka Holding...

2024-04-24 09:30:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio solidly outperformed the MSCI AC World Index. Holdings in health ca...

2024-04-11 08:36:33 ET More on Alpine Immune Sciences Alpine Immune Sciences, Inc. (ALPN) Q4 2023 Earnings Call Transcript Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug Vertex enters into agreement to acquire Alpine Immune Sciences ...

2024-01-25 15:30:27 ET Summary Vera Therapeutics, Inc. stock price soared over 35% today as it announced positive results from the open label extension of its Phase 2b ORIGIN clinical trial for atacicept in IgA nephropathy. The company's stock is up over 160% in the past year and ...

2024-01-21 13:30:00 ET Pharmaceutical companies would be wise to pay attention to developing new treatments for ADHD as there is a demand for improved drugs in the space. Currently, the medications of choice for the condition are stimulant drugs, such as Takeda's ( NYSE: TAK ) V...

2023-11-20 11:49:37 ET Summary Intra-Cellular Therapies, Inc. is a mid-cap biopharmaceutical company focused on developing treatments for neuropsychiatric and neurological disorders. The company's commercial asset, Caplyta, has achieved significant sales growth and is an exciting ...

2023-11-20 11:18:10 ET More on Medtronic Medtronic: 3 Key Issues To Consider Ahead Of Fiscal Q2 2024 Earnings Medtronic Stock Is Simply Too Cheap To Ignore Medtronic Faces Potential Decline Despite Financial Strength Medtronic Q2 2024 Earnings Preview ...

2023-11-10 10:34:03 ET More on Vera Therapeutics Vera Therapeutics' Promising Atacicept Drug Targets IgAN Guggenheim starts Vera at buy, sees IgAN drug as "well positioned" Seeking Alpha’s Quant Rating on Vera Therapeutics Historical earnings data for ...